POST Online Media Lite Edition



 

Pfizer starts clinical trial for coronavirus vaccine

Christian Fernsby |
Pfizer and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent coronavirus.

Article continues below



Topics: PFIZER    CORONAVIRUS   

The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study.

The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age).

The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age.

Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity.

Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine, with the University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center to begin enrollment shortly.


What to read next

AVEO Pharmaceuticals pays $4m to settle SEC fraud charges
AstraZeneca board rejects Pfizer's final proposal
Unredacted information shows unbelievable greed of Teva Pharmaceuticals